Učitavanje...
BRAF-directed Therapy in Metastatic Colorectal Cancer
Activating BRAF mutations occur in approximately 5–10% of metastatic colorectal cancer (mCRC) patients, mostly V600E mutation, and it is associated with distinct clinical and pathological features. To date, there are no approved treatments to target this mutation. BRAF inhibitor monotherapy has limi...
Spremljeno u:
| Izdano u: | Cancer J |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2016
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4922502/ https://ncbi.nlm.nih.gov/pubmed/27341594 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PPO.0000000000000189 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|